Publications by authors named "Moeka Yasue"
Article Synopsis
- Olaparib and niraparib, PARP inhibitors used in ovarian cancer treatment, are effective but cause high rates of nausea and vomiting in patients, with no established antiemetic guidelines.
- A study involving 134 patients aimed to monitor the incidence of nausea and vomiting over 21 days, finding that only 21.7% received preventive antiemetic therapy.
- The overall vomiting incidence was 16.3%, with lower rates for niraparib (10.3%) compared to olaparib (18.6%), suggesting they pose a low risk for emesis and may not require routine prophylactic antiemetics.
During the production of orexin A and B from preproorexin, a common precursor protein, in hypothalamic orexin neurons, C-terminal peptide (herein called preproorexin C-peptide) is concomitantly produced via post-translational processing. The predicted three-dimensional structure of preproorexin C-peptide is similar among mammalian species, suggestive of a conserved function in the mammalian brain. However, C-peptide has long been regarded as a non-functional peptide.
View Article and Find Full Text PDFObjectives: Although use of AUC-guided vancomycin dosing was recommended in the revised 2020 consensus guideline, collection of multiple vancomycin serum samples to calculate AUC may cause clinical complications. AUC calculated from trough-only data (one-point AUC-guided dosing) has not been sufficiently validated. The aim of the present study was to compare the incidence of nephrotoxicity following the change from trough-guided to one-point AUC-guided dosing.
View Article and Find Full Text PDFBackground/aim: Nausea and vomiting are two of the most distressing adverse events of cancer radiotherapy. The aim of this study was to examine the control rate and risk factors associated with nausea and vomiting in patients with cervical cancer receiving radiotherapy.
Patients And Methods: This retrospective study examined patients with cervical cancer who received radiotherapy alone or with concomitant cisplatin.
Introduction: While the revised 2020 consensus guideline recommends the use of area under the concentration-time curve (AUC)-guided vancomycin monitoring, collecting multiple vancomycin serum samples to calculate the AUC may cause clinical complications. The aim of the present retrospective study was to evaluate whether AUC-guided vancomycin monitoring, in which AUC was calculated based on a single trough concentration, is a better predictor of nephrotoxicity than trough-guided monitoring in patients receiving vancomycin therapy.
Methods: A single-center, retrospective cohort study was conducted at the 614-bed Gifu University Hospital in Japan.